Core Viewpoint - Shenzhou Cell announced that its subsidiary, Shenzhou Cell Engineering Co., Ltd., received approval from the National Medical Products Administration for clinical trials of its self-developed product SCT640C injection for the treatment of adult rheumatoid arthritis [1] Company Summary - Shenzhou Cell's subsidiary has been granted permission to conduct clinical trials, indicating progress in its drug development pipeline [1] - The approval is specifically for SCT640C injection, which targets adult rheumatoid arthritis, a significant market in the pharmaceutical industry [1] Industry Summary - The approval from the National Medical Products Administration highlights the regulatory support for innovative drug development in China [1] - The focus on rheumatoid arthritis treatment reflects the growing demand for effective therapies in this therapeutic area [1]

Core Viewpoint - Shenzhou Cell's subsidiary has received approval for clinical trials of SCT640C injection for adult rheumatoid arthritis, indicating progress in the development of treatments for autoimmune diseases [1] Group 1 - Shenzhou Cell announced that its subsidiary, Shenzhou Cell Engineering Co., Ltd., has received the Drug Clinical Trial Approval Notice from the National Medical Products Administration [1] - SCT640C is a monoclonal antibody injection independently developed by the company for the treatment of autoimmune diseases [1]